Intelligence Brief — Life Sciences GTM
What moved in Life Sciences commercial markets this week. Named companies, specific numbers, and a play for each signal. Published Tuesday and Friday by MarlowIQ.
Charles River signs definitive agreements to sell CDMO business to GI Partners and European Discovery Services to IQVIA.
Charles River filed on July 28 announcing definitive agreements to sell its CDMO and Cell Solutions businesses to GI Partners and its European Discovery Services assets to IQVIA in separate transactions. The move consolidates CRL around safety assessment and preclinical services. GI Partners now controls a Tier 1-branded CDMO asset and IQVIA absorbs an early-stage discovery services footprint that competing CROs had assumed CRL would defend.
Two structural competitive moves land in one filing. Preferred provider slates for European sponsor programs open in the transition window while asset ownership, contract novation, and account team continuity resolve. CDMOs competing against Lonza, Catalent, and Thermo Patheon now face a private equity-backed challenger under a Tier 1 name, and CROs with European early-stage exposure face an expanded IQVIA discovery footprint. This is a one-quarter repositioning window, not a passive news item.
CDMOs and CROs with active European sponsor programs should re-baseline competitive alternatives against the new GI Partners CDMO and IQVIA discovery entities within two weeks, before Q3 procurement cycles close and preferred provider slates lock.
Agilent stacks expanded FDA companion diagnostic approval, a $950M Biocare acquisition, and an OpenAI and BCG AI collaboration in one quarter.
Agilent reported Q2 fiscal 2026 revenue of $1.835B and net income of $339M, with six-month profit at $644M. Inside the same quarter it advanced a $950M Biocare acquisition, received expanded FDA approval for PD-L1 IHC 22C3 pharmDx in esophageal and gastroesophageal junction carcinoma, and launched an AI collaboration with OpenAI and Boston Consulting Group. Guidance was raised.
Agilent is repositioning analytical instruments toward companion diagnostics and AI-native workflows, the two segments least exposed to the current instruments capex red print at monitored tools peers. Pharma companion diagnostic accounts and AI-workflow procurement conversations are the immediate competitive surface where mass spec and chromatography peers will feel the pressure over the next two quarters.
Analytical instruments peers with mass spec and chromatography portfolios should refresh companion diagnostics and AI-workflow positioning packages for named pharma dx accounts within the quarter, ahead of Agilent's Q3 print.
mIQ (0–100): our composite score of how ready an account is to buy.
Three accounts moved in mIQ this week on confirmed procurement and pipeline signals.
Full access shows mIQ scores for all 950+ accounts and the ranked opportunity board.
4 signals this week — each with a named play and specific timing.
Full access: mIQ scores on 950+ accounts, active clinical trial pipeline, and every competitor baseline — updated weekly.
Request full access →2 more signals in this brief.
MarlowIQ is in private preview. Request access to read every signal and receive Tuesday and Friday briefs in your inbox.
By invitation — design partners only.
Go deeper on any signal — Ask Marlow →